As reported in The Wall Street
Journal, Bloomberg, Reuters and
other media outlets, Paul, Weiss client Elanco U.S., Inc., a
subsidiary of Paul, Weiss client Eli Lilly and Company, announced
an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S.
feline, canine and rabies vaccines portfolio, as well as a fully
integrated manufacturing and R&D site, for $885